Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine (Bio Farma)
- Development stage
- Unknown
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Bivalent oral poliovirus vaccine (bOPV) is a live-attenuated vaccine containing attenuated Sabin strains of poliovirus types 1 and 3. It was developed to replace the trivalent oral poliovirus vaccine (tOPV) as part of the Global Polio Eradication Initiative, following the eradication of wild poliovirus type 2. By removing the type 2 component, bOPV reduces the risk of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of circulating vaccine-derived polioviruses (cVDPVs) related to type 2. The vaccine is administered orally, where it replicates in the intestinal tract to induce both local mucosal immunity (IgA) and systemic humoral immunity (IgG). PT Bio Farma is a major developer and manufacturer of this vaccine, which is widely used in routine childhood immunization programs and mass vaccination campaigns globally.
- Brand names
- bOPV Bio Farma
- Other names
- bivalent OPVSabin types 1 and 3 oral poliovirus vaccine
02
Targets
PVR
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine (Bio Farma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine (Bio Farma).